The Food and Drug Administration has issued final guidance revising its recommendations for testing donated whole blood and blood components for Zika virus. The guidance recommends that establishments collecting whole blood and blood components test all donations collected in the U.S. and its territories using minipool (MP) or individual donation nucleic acid testing, or collect and prepare blood components using pathogen reduction technology with an FDA-approved pathogen-reduction device. The guidance also recommends that establishments using MP NAT convert to ID NAT if screening identifies a Zika-reactive donation or public health authorities identify an increased risk for Zika transmission in the area. FDA previously recommended using ID NAT for all blood donations or pathogen reduction for indicated blood components. The agency said it expects the new recommendations “to adequately and appropriately detect early infections in an outbreak, while reducing the burden of ID NAT testing.”

Related News Articles

Headline
The U.S. Food and Drug Administration May 23 authorized marketing of a diagnostic test for detecting Zika virus antibodies in human blood.
Headline
The Senate last night voted 85-7 to pass an $857 billion spending package, which includes bills that would fund the departments of Health and Human Services,…
Headline
About 14% of babies age one or older who were born in U.S. territories to pregnant women infected with Zika virus since 2016 have at least one health problem…
Headline
Illnesses from mosquito, tick and flea bites more than tripled in the United States between 2004 and 2016 to more than 96,000 a year.
Headline
Birth defects associated with Zika virus infection during pregnancy increased 21% in the last half of 2016 in Puerto Rico and portions of Florida and Texas…
Headline
The Centers for Disease Control and Prevention last week issued